Opinion of the Transparency Council – acidum mycophenolicum
At its meeting on 13 January 2025, the Transparency Council adopted opinion No. 9/2025 on the inclusion in reimbursement of medicines containing the active substance acidum mycophenolicum in the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. condition after transplantation of a limb, cornea, tissues or cells